FDA warns AstraZeneca for alleged off-label promotion
Pharma Compliance Alert, December 10, 2008
An AstraZeneca sales representative allegedly promoted the company’s antipsychotic Seroquel and Seroquel XL for an off-label use during an unsolicited sales call with a physician, according to an FDA warning letter.
According to the FDA, the sales representative promoted the drugs to treat major depressive disorder, which is not an FDA-approved use. When the physician requested written information supporting this claim, the company allegedly mailed the physician a list of eight clinical trials supporting the off-label use.
The FDA said the oral statements made by the sales representative and the information provided in the mailing suggests a new intended use for Seroquel and Seroquel XL for which the products lack adequate directions. AstraZeneca’s disclaimer in the physician letter that it does not recommend the off-label use is not sufficient to mitigate the off-label promotion, according to the FDA.
Comments
0 comments on “FDA warns AstraZeneca for alleged off-label promotion ”
Related Products
-
ePharm5 InDepth
EPharm5 e-mail newsletter delivers the top 5 developments in pharma business innovation, with original research, interviews...
-
Medical Environment Update
Timely medical compliance news from OSHA, CDC, EPA, and other regulatory agencies!
-
Bloodborne Pathogens Training Video
Meets OSHA requirements for training employees on the bloodborne pathogens standard!
-
Hazard Communication Standard Training Video
Meets OSHA requirements for training employees on the Hazard Communication Standard!
-
Needlestick Prevention Training Video
Highlighting the five most frequent needlestick scenarios, this training video instructs frontline healthcare staff on on...
Most Popular
- Articles
-
- HIPAA Q&A: Flu shot requirement for hospital employees
- Running an effective peer review committee meeting
- HealthDataInsights posts new issues for medical necessity claims
- Sneak Peek: Effort underway to establish caseload benchmarks
- Q/A: Coding for telescopic intraocular lens
- New FAQ posted on storing laryngoscope blades
- Tip: Perform your own internal investigation prior to government audit
- HIPAA 5010 deadline extended, but threat remains, says AMA
- HHS task force: Consider privacy, security with text messages
- What does case-mix index mean to you?
- E-mailed
-
- Running an effective peer review committee meeting
- HIPAA Q&A: Flu shot requirement for hospital employees
- HHS task force: Consider privacy, security with text messages
- What does case-mix index mean to you?
- Q/A: Coding for telescopic intraocular lens
- Q/A: Correct use of modifier -PT
- Tip: Correctly code bilateral pain management procedures
- "Wall fountains" may be spreading Legionnaires to patients, visitors
- 2012 CPT code changes for ASCs: Shoulder and knee scopes and pain management
- COT basics to best
- Searched